Celebrating 75 years of oestradiol

Journal of Molecular Endocrinology

Volumn 55, Issue 3, 2015, Pages T1-T20

  Simpson, Evan ^a   Santen, Richard J ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Aromatase; Oestradiol; Oestrogen; Regulation

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR; ESTRADIOL; ESTROGEN; G PROTEIN COUPLED RECEPTOR; INSULIN GROWTH FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN; UNCLASSIFIED DRUG;

BIOSYNTHESIS; BONE METABOLISM; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL MIGRATION; DRUG MECHANISM; ENDOMETRIUM CANCER; ENDOTHELIUM CELL; ENZYME ANALYSIS; ENZYME PURIFICATION; ENZYME REGULATION; ENZYME STRUCTURE; ESTROGEN SYNTHESIS; ESTROGEN THERAPY; HUMAN; LIVER CELL; MENOPAUSE; METABOLIC SYNDROME X; MITOCHONDRION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SEXUAL DEVELOPMENT; ANIMAL; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG DEVELOPMENT; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HISTORY; ISOLATION AND PURIFICATION; MALE; METABOLISM; PHYSIOLOGY;

ANIMALS; AROMATASE; BREAST NEOPLASMS; DRUG DISCOVERY; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HISTORY, 20TH CENTURY; HUMANS; MALE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE;

EID: 84947770410     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-15-0128     Document Type: Review

References (147)

1. Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER & Bulun SE 1998 Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. Journal of Clinical Endocrinology and Metabolism 83 1797-1800.
2. Albright F & Ellsberg R 1990 Uncharted seas, pp 3-95. Portland, OR, USA: Kalmia Press.
3. Allen E 1924 The hormone of the ovarian follicle; its localization and action in test animals, and additional points bearing upon the internal secretion of the ovary. American Journal of Anatomy 84 133-154. (doi:10.1002/aja.1000340104)
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. 2004 Effects of conjugated equine oestrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 291 1701-1712. (doi:10.1001/jama.291.14.1701)
5. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D et al. 2012 Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet. Oncology 13 476-486. (doi:10.1016/S1470-2045(12)70075-X)
6. Arnal JF, Fontaine C, Abot A, Valera MC, Laurell H, Gourdy P & Lenfant F 2013 Lessons from the dissection of the activation functions (AF-1 and AF-2) of the oestrogen receptor a in vivo. Steroids 78 576-582. (doi:10.1016/j.steroids.2012.11.011)
7. Beatson GT1896 On the treatment ofinoperable cases ofcarcinoma ofthe mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2 162-165. (doi:10.1016/S0140-6736(01)72384-7)
8. Bender CM, Merriman JD, Gentry AL, Ahrendt GM, Berga SL, Brufsky AM, Casillo FE, Dailey MM, Erickson KI, Kratofil FM et al. 2015 Patterns of change in cognitive function with anastrozole therapy. Cancer 121 2627-2636. (doi:10.1002/cncr.29393)
9. Block GE, Ellis RS, DeSombre E & Jensen E. 1978 Correlation of estrophilin content ofprimary mammary cancer to eventual endocrine treatment. Annals of Surgery 188 372-376. (available at: http://journals.lww.com/annalsofsurgery/Abstract/1978/09000/Correlation_of_Estrophilin_Content_of_Primary.12.aspx)
10. Bolton S & Siiteri PK 1969 Studies of aromatizing enzymes of the placenta. In 16th Annual Meeting of the Society for Gynecologic Investigation, March 20-21, p 37. Denver, CO, USA: Society for Gynecologic Investigation.
11. Brodie HJ, Hayano M & Gut M 1962 The stereochemical course of catalytic hydrogenation of ring A unsaturated steroids. Journal ofthe American Chemical Society 84 3766-3767. (doi:10.1021/ja00878a033)
12. Brodie HJ, Kripalani KJ & Possanza G 1969 Studies on the mechanism of oestrogen biosynthesis. VI. The stereochemistry of hydrogen elimination at C-2 during aromatization. Journal ofthe American Chemical Society 91 1241-1242. (doi:10.1021/ja01033a050)
13. Brodie AM, Schwarzel WC, Shaikh AA & Brodie HJ. 1977 The effect ofan aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 1684-1695. (doi:10.1210/endo-100-6-1684)
14. Brodie AM, Garrett WM, Hendrickson JR, Tsai-Morris CH, Marcotte PA & Robinson CH 1981 Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 38 693-702. (doi:10.1016/0039-128X (81)90087-8)
15. Brown KA, Mclnnes KJ, Hunger NI, Oakhill JS, Steinberg GR & Simpson ER 2009 Subcellular localization ofcyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Research 69 5392-5399. (doi:10.1158/0008-5472.CAN-09-0108)
16. Brown KA, Hunger NI, Docanto M & Simpson ER 2010 Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research and Treatment 123 591-596. (doi:10.1007/s10549-010-0834-y)
17. Bulun SE 2014 Aromatase and oestrogen receptor a deficiency. Fertility and Sterility 101 323-329. (doi:10.1016/j.fertnstert.2013.12.022)
18. Bulun SE, Takayama K, Suzuki T, Sasano H, Yilmaz B & Sebastian S 2004 Organization of the human aromatase p450 (CYP19) gene. Seminars in Reproductive Medicine 22 5-9. (doi:10.1055/s-2004-823022)
19. Butenandt A 1929 Uber progynon ein krytallisiertes weibliches exualhormon. Die Naturwissenschaften 17 879. (doi:10.1007/BF01506919)
20. Cash R, Brough AJ, Cohen MN & Satoh PS 1967 Aminoglutethimide (Elipten-Ciba) as an inhibitor ofadrenal steroidogenesis: mechanism of action and therapeutic trial. Journal ofClinical Endocrinology and Metabolism 27 1239-1248. (doi:10.1210/jcem-27-9-1239)
21. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R et al. 2006 Catechol oestrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta 1766 63-78.
22. Chakraborty J, Hopkins R & Parke DV 1972 Inhibition studies on the aromatization ofandrost-4-ene-3,17-dione by human placental microsomal preparations. Biochemical Journal 130 19P-20P. (doi:10.1042/bj1300019Pb)
23. Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas GD, Mineo C, Yuhanna IS, Kim SH et al. 2010 Non-nuclear oestrogen receptor a signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. Journal ofClinical Investigation 120 2319-2330. (doi:10.1172/JCI38291)
24. Chen H, Wang JP, Santen RJ & Yue W 2015 Adenosine monophosphate activated protein kinase (AMPK), a mediator ofestradiol-induced apoptosis in long-term oestrogen deprived breast cancer cells. Apoptosis 20 821-830. (doi:10.1007/s10495-015-1111-7)
25. Coen P, Kulin H, Ballantine T, Zaino R, Frauenhoffer E, Boal D, Inkster S, Brodie A & Santen R 1991 An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. New England Journal ofMedicine 324 317-322. (doi:10.1056/NEJM199101 313240507)
26. Corbin CJ, Graham-Lorence S, McPhaul M, Mason JI, Mendelson CR & Simpson ER 1988 Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. PNAS 85 8948-8952. (doi:10.1073/pnas.85.23.8948)
27. Couse JF, Lindzey J, Grandien K, Gustafsson JA & Korach KS 1997 Tissue distribution and quantitative analysis ofoestrogen receptor-a (ERa) and oestrogen receptor-b (ERb) messenger ribonucleic acid in the wild-type and ERa-knockout mouse. Endocrinology 138 4613-4621.
28. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG & Gustafsson JA 2006 International Union ofPharmacology. LXIV. Estrogen receptors. Pharmacological Reviews 58 773-781. (doi:10.1124/pr.58.4.8)
29. Doisy EA 1976 An autobiography. Annual Review ofBiochemistry 45 1-12. (doi:10.1146/annurev.bi.45.070176.000245)
30. Doisy EA, Thayer S & Veler CD 1929 The crystals of the follicular ovarian hormone. Proceedings ofthe Society for Experimental Biology and Medicine 27 417-419. (doi:10.3181/00379727-27-4791)
31. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL & Coombes RC 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 1957-1961.
32. Dunbier AK, Anderson H, Folkerd E, Ghazoui Z, Smith IE, Ellis MJ, Dowsett M & Neoadjuvant Letrozole Study Group 2008 Expression of oestrogen responsive genes in breast cancers correlates wtih plasma oestradiol levels in post-menopausal women. Cancer Research 69 63 (31st Annual San Antonio Breast Cancer Symposium, abstract #63, 2008).
33. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A et al. 2009 Lower-dose vs high-dose oral oestradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. Journal ofthe American Medical Association 302 774-780. (doi:10.1001/jama.2009.1204)
34. Evans CT, Ledesma DB, Schulz TZ, Simpson ER & Mendelson CR 1986 Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. PNAS 83 6387-6391. (doi:10.1073/pnas.83.17.6387)
35. Favia AD, Cavalli A, Masetti M, Carotti A & Recanatini M 2006 Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62 1074-1087. (doi:10.1002/prot.20829)
36. Filardo EJ & Thomas P 2012 Minireview: G protein-coupled oestrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 153 2953-2962. (doi:10.1210/en.2012-1061)
37. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ et al. 2013 Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine 369 1011-1022. (doi:10.1056/NEJMoa1206168)
38. Flamini MI, Sanchez AM, Genazzani AR & Simoncini T 2011 Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertility and Sterility 95 722-726. (doi:10.1016/j.fertnstert.2010.08.039)
39. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG & Cavalieri EL 2008 The molecular etiology of breast cancer: evidence from biomarkers of risk. International Journal ofCancer 122 1949-1957. (doi:10.1002/ijc.23329)
40. Gaikwad NW, Yang L, Weisenburger DD, Vose J, Beseler C, Rogan EG & Cavalieri EL 2009 Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 14 502-512. (doi:10.3109/13547500903121715)
41. Ghosh D, Griswold J, Erman M & Pangborn W 2009 Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 45 7 219-223. (doi:10.1038/nature07614)
42. Graham-Lorence S, Amarneh B, White RE, Peterson JA & Simpson ER 1995 A three-dimensional model of aromatase cytochrome P450. Protein Science 4 1065-1080. (doi:10.1002/pro.5560040605)
43. Griffiths CT, Hall TC, Saba Z, Barlow JJ & Nevinny HB 1973 Preliminary trial of aminoglutethimide in breast cancer. Cancer 32 31-37. (doi:10.1002/1097-0142(197307)32:1<31::AID-CNCR2820320104 >3.0.CO;2-5)
44. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R et al. 2009 Regulatory role of G protein-coupled oestrogen receptor for vascular function and obesity. Circulation Research 104 288-291. (doi:10.1161/CIRCRESAHA.108.190892)
45. Hall PF, Chen S, Nakajin S, Shinoda M & Shively JE 1987 Purification and characterization ofaromatase from human placenta. Steroids 50 37-50. (doi:10.1016/0039-128X(83)90060-0)
46. Ham S, Meachem SJ, Choong CS, Charles AK, Baynam GS, Jones TW, Samarajeewa NU, Simpson ER & Brown KA 2013 Overexpression of aromatase associated with loss of heterozygosity of the STK11 gene accounts for prepubertal gynecomastia in boys with Peutz-Jeghers syndrome. Journal ofClinical Endocrinology and Metabolism 98 E1979-E1987. (doi:10.1210/jc.2013-2291)
47. Hamilton KJ, Arao Y & Korach KS 2014 Estrogen hormone physiology: reproductive findings from oestrogen receptor mutant mice. Reproductive Biology 14 3-8. (doi:10.1016/j.repbio.2013.12.002)
48. Harada N 1988 Cloning of a complete cDNA encoding human aromatase: immunochemical identification and sequence analysis. Biochemical and Biophysical Research Communications 156 725-732. (doi:10.1016/S0006-291X(88)80903-3)
49. Harada N, Yamada K, Saito K, Kibe N, Dohmae S & Takagi Y 1990 Structural characterization of the human oestrogen synthetase (aromatase) gene. Biochemical and Biophysical Research Communications 166 365-372. (doi:10.1016/0006-291X(90)91954-Q)
50. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA & Katzenellenbogen BS 2006 Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of oestrogen action. Molecular Endocrinology 20 491-502. (doi:10.1210/me.2005-0186)
51. Hickey GJ, Krasnow JS, Beattie WG & Richards JS 1990 Aromatase cytochrome P450 in rat ovarian granulosa cells before and after luteinization: adenosine 3',5'-monophosphate-dependent and independent regulation. Cloning and sequencing of rat aromatase cDNA and 5' genomic DNA. Molecular Endocrinology 4 3-12. (doi:10.1210/mend-4-1-3)
52. Hong Y, Yu B, Sherman M, Yuan YC, Zhou D & Chen S 2007 Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Molecular Endocrinology 21 401-414. (doi:10.1210/me.2006-0281)
53. Hong Y, Li H, Ye J, Miki Y, Yuan YC, Sasano H, Evans DB & Chen S 2009 Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity. PLoS ONE 4 e8050. (doi:10.1371/journal.pone.0008050)
54. Hong Y, Li H, Yuan YC & Chen S 2010 Sequence-function correlation of aromatase and its interaction with reductase. Journal ofSteroid Biochemistry and Molecular Biology 118 203-206. (doi:10.1016/j.jsbmb.2009.11.010)
55. Huffman MN, Thayer SA & Doisy EA 1940 The isolation of a-dihydrotheelin from human placenta. Journal ofBiological Chemistry 133 567-571.
56. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT et al. 2005 Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer 12 1071-1082. (doi:10.1677/erc.1.01038)
57. Kellis JT Jr & Vickery LE 1987 Purification and characterization of human placental aromatase cytochrome P-450. Journal ofBiological Chemistry 262 4413-4420.
58. Key T, Appleby P, Barnes I, Reeves G & Endogenous Hormones and Breast Cancer Collaborative Group 2002 Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute 94 606-616. (doi:10.1093/jnci/94.8.606)
59. Kim JK & Levin ER 2006 Estrogen signaling in the cardiovascular system. Nuclear Receptor Signaling 4 e013.
60. Koymans LM, Moereels H & Vanden BH 1995 A molecular model for the interaction between vorozole and other non-steroidal inhibitors and human cytochrome P450 19 (P450 aromatase). Journal ofSteroid Biochemistry and Molecular Biology 53 191-197. (doi:10.1016/0960-0760(95)00033-V)
61. Labrie F 2015 All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. Journal of Steroid Biochemistry and Molecular Biology 145 133-138. (doi:10.1016/j.jsbmb.2014.06.001)
62. Laughton CA, Zvelebil MJ & Neidle S 1993 A detailed molecular model for human aromatase. Journal ofSteroid Biochemistry and Molecular Biology 44 399-407. (doi:10.1016/0960-0760(93)90243-P)
63. Levin ER. 2009 Hormone action and breast cancer. Cancer Treatment and Research 147 1-10.
64. Levin ER. 2014a Extranuclear oestrogen receptor's roles in physiology: lessons from mouse models. American Journal ofPhysiology. Endocrinology and Metabolism 307 E133-E140. (doi:10.1152/ajpendo.00626.2013)
65. Levin ER 2014b Translating extranuclear steroid receptor signaling to clinical medicine. Hormones & Cancer 5 140-145. (doi:10.1007/s12672-014-0179-9)
66. Levin ER 2015 Extranuclear steroid receptors are essential for steroid hormone actions. Annual Review of Medicine 66 271-280. (doi:10.1146/annurev-med-050913-021703)
67. Lewis JS, Osipo C, Meeke K & Jordan VC 2005 Estrogen-induced apoptosis in a breast cancer model resistant to long-term oestrogen withdrawal. Journal ofSteroid Biochemistry and Molecular Biology 94 131-141. (doi:10.1016/j.jsbmb.2004.12.032)
68. Li Y, Wang JP, Santen RJ, Kim TH, Park H, Fan P & Yue W 2010 Estrogen stimulation of cell migration involves multiple signaling pathway interactions. Endocrinology 151 5146-5156. (doi:10.1210/en.2009-1506)
69. Lipton A, Harvey HA, Santen RJ, Boucher A, White D, Bernath A, Dixon R, Richards G & Shafik A 1982 A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer 50 2265-2268. (doi:10.1002/1097-0142(19821201)50:11<2265::AID-CNCR2820501106>3.0.CO;2-)
70. Lonning PE 2009 Additive endocrine therapy for advanced breast cancer-back to the future. Acta Oncologica 48 1092-1101. (doi:10.3109/ 02841860903117816)
71. Lonning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S & Dowsett M 2011 Exploring breast cancer oestrogen disposition: the basis for endocrine manipulation. Clinical Cancer Research 17 4948-4958. (doi:10.1158/1078-0432.CCR-11-0043)
72. Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA & Katzenellenbogen BS 2008 Nuclear and extranuclear pathway inputs in the regulation of global gene expression by oestrogen receptors. Molecular Endocrinology 22 2116-2127. (doi:10.1210/me.2008-0059)
73. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER & Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and oestradiol treatment. Journal ofClinical Endocrinology and Metabolism 89 61-70. (doi:10.1210/jc.2003-030313)
74. Magnani L & Lupien M 2014 Chromatin and epigenetic determinants of oestrogen receptor a (ESR1) signaling. Molecular and Cellular Endocrinology 382 633-641. (doi:10.1016/j.mce.2013.04.026)
75. Mahendroo MS, Means GD, Mendelson CR & Simpson ER 1991 Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. Journal ofBiological Chemistry 266 11276-11281.
76. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ et al. 2013 Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases ofthe Women's Health Initiative randomized trials. Journal ofthe American Medical Association 310 1353-1368. (doi:10.1001/jama.2013.278040)
77. Marjon NA, Hu C, Hathaway HJ & Prossnitz ER 2014 G protein-coupled oestrogen receptor regulates mammary tumorigenesis and metastasis. Molecular Cancer Research 12 1644-1654. (doi:10.1158/1541-7786.MCR-14-0128-T)
78. Marsh DA, Brodie HJ, Garrett W, Tsai-Morris CH & Brodie AM 1985 Aromatase inhibitors. Synthesis and biological activity of androstene-dione derivatives. Journal ofMedicinal Chemistry 28 788-795. (doi:10.1021/jm00383a017)
79. McPhaul MJ, Noble JF, Simpson ER, Mendelson CR & Wilson JD. 1988 The expression of a functional cDNA encoding the chicken cytochrome P-450arom (aromatase) that catalyzes the formation of oestrogen from androgen. Journal ofBiological Chemistry 263 16358-16363.
80. Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR & Simpson ER. 1989 Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for oestrogen biosynthesis. Journal ofBiological Chemistry 264 19385-19391.
81. Means GD, Kilgore MW, Mahendroo MS, Mendelson CR & Simpson ER 1991 Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Molecular Endocrinology 5 2005-2013. (doi:10.1210/mend-5-12-2005)
82. Mendelson CR, Wright EE, Evans CT, Porter JC & Simpson ER 1985 Preparation and characterization of polyclonal and monoclonal antibodies against human aromatase cytochrome P-450 (P-450AROM), and their use in its purification. Archives of Biochemistry and Biophysics 243 480-491. (doi:10.1016/0003-9861(85)90525-9)
83. Meyer AS 1955 Conversion of19-hydroxy-delta 4-androstene-3,17-dione to oestradiol by endocrine tissue. Biochimica et Biophysica Acta 17 441-442. (doi:10.1016/0006-3002(55)90395-4)
84. Meyer AS, Hayano M, Lindberg MC, Gut M & Rodgers OG 1955 The conversion of delta 4-androstene-3,17-dione-4-C14 and dehydroepiandrosterone by bovine adrenal homogenate preparations. Acta Endocrinologica 18 148-168.
85. Morato T, Hayano M, Dorfman RI & Axelrod LR 1961 The intermediate steps in the biosynthesis of oestrogen from androgens. Biochemical and Biophysical Research Communications 6 334-338. (doi:10.1016/0006-291X(61)90140-1)
86. Muto N & Tan L. 1985 Purification of oestrogen synthetase by high-performance liquid chromatography. Two membrane-bound enzymes from the human placenta. Journal ofChromatography 326 137-146. (doi:10.1016/S0021-9673(01)87439-2)
87. Newsome HH, Brown PW, Terz JJ & Lawrence W Jr 1977 Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer 39 542-546. (doi:10.1002/1097-0142(197702)39:2<542::AID-CNCR2820390224> 3.0.CO;2-R)
88. Newsome HH Jr, Brown PW, Terz JJ & Lawrence W Jr 1978 Medical adrenalectomy and plasma steroids in advanced breast carcinoma. Surgery 83 83-89.
89. Osawa Y, Yoshida N, Fronckowiak M & Kitawaki J 1987 Immunoaffinity purification of aromatase cytochrome P-450 from human placental microsomes, metabolic switching from aromatization to 1b and 2b -monohydroxylation, and recognition of aromatase isozymes. Steroids 50 11-28. (doi:10.1016/0039-128X(83)90058-2)
90. Pasanen M & Pelkonen O 1981 Solubilization and partial purification of human placental cytochromes P-450. Biochemical and Biophysical Research Communications 103 1310-1317. (doi:10.1016/0006-291X(81)90265-5)
91. Pedram A, Razandi M, Kim JK, O'Mahony F, Lee EY, Luderer U & Levin ER 2009 Developmental phenotype of a membrane only oestrogen receptor a (MOER) mouse. Journal ofBiological Chemistry 284 3488-3495. (doi:10.1074/jbc.M806249200)
92. Pietras RJ & Szego CM 1977 Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265 69-72. (doi:10.1038/265069a0)
93. Preston-Martin S, Pike MC, Ross RK, Jones PA & Henderson BE 1990 Increased cell division as a cause of human cancer. Cancer Research 50 7415-7421.
94. Preston-Martin S, Pike MC, Ross RK & Henderson BE 1993 Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environmental Health Perspectives 101 (Suppl 5) 137-138. (doi:10.1289/ehp.93101s5137)
95. Razandi M, Pedram A, Jordan VC, Fuqua S & Levin ER 2013 Tamoxifen regulates cell fate through mitochondrial oestrogen receptor b in breast cancer. Oncogene 32 3274-3285. (doi:10.1038/onc.2012.335)
96. Robertson KM, O'Donnell L, Jones ME, Meachem SJ, Boon WC, Fisher CR, Graves KH, McLachlan RI & Simpson ER 1999 Impairment of spermatogenesis in mice lacking a functional aromatase (cyp 19) gene. PNAS 96 7986-7991. (doi:10.1073/pnas.96.14.7986)
97. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM & Cavalieri EL 2003 Relative imbalances in oestrogen metabolism and conjugation in breast tissue ofwomen with carcinoma: potential biomarkers of susceptibility to cancer. Carcino-genesis 24 697-702. (doi:10.1093/carcin/bgg004)
98. Saeed M, Rogan E, Fernandez SV, Sheriff F, Russo J & Cavalieri E 2007 Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. International Journal ofCancer 120 1821-1824. (doi:10.1002/ijc.22399)
99. Sanchez AM, Flamini MI, Zullino S, Gopal S, Genazzani AR & Simoncini T 2011 Estrogen receptor-{a} promotes endothelial cell motility through focal adhesion kinase. Molecular Human Reproduction 17 219-226. (doi:10.1093/molehr/gaq097)
100. Santen RJ 1981 Suppression ofoestrogen with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Research and Treatment 1 183-202. (doi:10.1007/BF01806259)
101. Santen RJ 2015 Vaginal administration ofestradiol: effects ofdose, preparation and timing on plasma oestradiol levels. Climacteric 18 121-134. (doi:10.3109/13697137.2014.947254)
102. Santen RJ, Lipton A & Kendall J 1974 Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. Journal of the American Medical Association 230 1661-1665. (doi:10.1001/jama.1974.03240120029015)
103. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978a Aminoglutethimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265. (doi:10.1210/jcem-47-6-1257)
104. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978b Aminoglutethimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265. (doi:10.1210/jcem-47-6-1257)
105. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C et al. 1981 A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 305 545-551. (doi:10.1056/NEJM198109033051003)
106. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E & Wells SA 1982 Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Annals ofInternal Medicine 96 94-101. (doi:10.7326/0003-4819-96-1-94)
107. Santen RJ, Manni A, Harvey H & Redmond C 1990 Endocrine treatment ofbreast cancer in women. Endocrine Reviews 11 221-265. (doi:10.1210/edrv-11-2-221)
108. Santen RJ, Boyd NF, Chlebowski RT, Cummings S, Cuzick J, Dowsett M, Easton D, Forbes JF, Key T, Hankinson SE et al. 2007 Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-Related Cancer 14 169-187. (doi:10.1677/ERC-06-0045)
109. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M et al. 2010 Postmenopausal hormone therapy: an Endocrine Society scientific statement. Journal of Clinical Endocrinology and Metabolism 95 (7 Suppl 1) s1-s66. (doi:10.1210/jc.2009-2509)
110. Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF et al. 2014 BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Research 74 2773-2784. (doi:10.1158/0008-5472.CAN-13-2611)
111. Schultz-Norton JR, Ziegler YS & Nardulli AM 2011 ERa-associated protein networks. Trends in Endocrinology and Metabolism 22 124-129. (doi:10.1016/j.tem.2010.11.005)
112. Selvaraj NG, Omi E, Gibori G & Rao MC 2000 Janus kinase 2 (JAK2) regulates prolactin-mediated chloride transport in mouse mammary epithelial cells through tyrosine phosphorylation of Na+-K+-2ClK cotransporter. Molecular Endocrinology 14 2054-2065.
113. Shozu M & Simpson ER 1998 Aromatase expression ofhuman osteoblast-like cells. Molecular and Cellular Endocrinology 139 117-129. (doi:10.1016/S0303-7207(98)00069-0)
114. Shozu M, Sumitani H, Segawa T, Yang HJ, Murakami K, Kasai T & Inoue M 2002 Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 ofthe aromatase P450 gene (CYP19). Journal ofClinical Endocrinology and Metabolism 87 2540-2548. (doi:10.1210/jcem.87.6.8533)
115. Simpson ER & Brown KA 2013 Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Molecular Endocrinology 27 715-725. (doi:10.1210/me.2013-1011)
116. Song RX 2007 Membrane-initiated steroid signaling action of oestrogen and breast cancer. Seminars in Reproductive Medicine 25 187-197. (doi:10.1055/s-2007-973431)
117. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J & Santen RJ 2001 Effect of long-term oestrogen deprivation on apoptotic responses of breast cancer cells to 17b-estradiol. Journal ofthe National Cancer Institute 93 1714-1723. (doi:10.1093/jnci/93.22.1714)
118. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R & Santen RJ 2004 The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of oestrogen receptor a to the plasma membrane. PNAS 101 2076-2081. (doi:10.1073/pnas.0308334100)
119. Song RX, Zhang Z, Chen Y, Bao Y & Santen RJ 2007 Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148 4091-4101. (doi:10.1210/en.2007-0240)
120. Steinach E & Kun H 1936 Wien Klin Wachr 49 16.
121. Steinach E & Kun H 1937 Transformation of male sex hormones into a substance with the action of a female hormone. Lancet 133 845. (doi:10.1016/S0140-6736(00)88745-0)
122. Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Hassan Murad M, Pinkerton JV & Santen RJ. 2015. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism [in press]. (doi:10.1210/jc.2015-2236)
123. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA & Dannenberg AJ 2012 Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discovery 2 356-365. (doi:10.1158/2159-8290.CD-11-0241)
124. Tanaka M, Telecky TM, Fukada S, Adachi S, Chen S & Nagahama Y 1992 Cloning and sequence analysis ofthe cDNA encoding P-450 aromatase (P450arom) from a rainbow trout (Oncorhynchus mykiss) ovary; relationship between the amount of P450arom mRNA and the production of oestradiol-17b in the ovary. Journal ofMolecular Endocrinology 8 53-61. (doi:10.1677/jme.0.0080053)
125. Terashima M, Toda K, Kawamoto T, Kuribayashi I, Ogawa Y, Maeda T & Shizuta Y 1991 Isolation of a full-length cDNA encoding mouse aromatase P450. Archives ofBiochemistry and Biophysics 285 231-237. (doi:10.1016/0003-9861(91)90354-L)
126. Thayer SA, Levin L & Doisy EA 1931 Characterization ofTheelol. Journal of Biological Chemistry 91 655-665.
127. Thompson EA Jr & Siiteri PK 1974 Utilization ofoxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. Journal of Biological Chemistry 249 5364-5372.
128. Thompson EA Jr & Siiteri PK 1979 Subcellular distribution ofaromatase in human placenta and ovary. Hormone Research 11 179-185. (doi:10.1159/000179053)
129. Toda K & Shizuta Y 1993 Molecular cloning of a cDNA showing alternative splicing of the 5'-untranslated sequence of mRNA for human aromatase P-450. European Journal of Biochemistry 213 383-389. (doi:10.1111/j.1432-1033.1993.tb17772.x)
130. Toda K, Terashima M, Mitsuuchi Y, Yamasaki Y, Yokoyama Y, Nojima S, Ushiro H, Maeda T, Yamamoto Y & Sagara Y 1989 Alternative usage of different poly(A) addition signals for two major species ofmRNA encoding human aromatase P-450. FEBS Letters 247 371-376. (doi:10.1016/0014-5793(89)81373-0)
131. Toda K, Terashima M, Kawamoto T, Sumimoto H, Yokoyama Y, Kuribayashi I, Mitsuuchi Y, Maeda T, Yamamoto Y & Sagara Y 1990 Structural and functional characterization of human aromatase P-450 gene. European Journal ofBiochemistry 193 559-565. (doi:10.1111/j.1432-1033.1990.tb19372.x)
132. Townsley JD & Brodie HJ 1968 Studies on the mechanism of oestrogen biosynthesis. 3. The stereochemistry ofaromatization ofC19 and C18 steroids. Biochemistry 7 33-40. (doi:10.1021/bi00841a005)
133. Tsai SA, Stefanick ML & Stafford RS 2011 Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 18 385-392. (doi:10.1097/gme.0b013e3181f43404)
134. Veler CD, Thayer S & Doisy EA. 1930 The preparation of the crystalline follicular ovarian hormone: theelin. Journal ofBiological Chemistry 87 357-371. (available at: http://www.jbc.org/content/87/2/357.citation)
135. Watkins ED. 2007 In The Estrogen Elixer: A History ofHormone Replacement in America. Baltimore, MD, USA: The Johns Hopkins Press.
136. Watters JJ, Chun TY, Kim YN, Bertics PJ & Gorski J 2000 Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Molecular Endocrinology 14 1872-1881. (doi:10.1210/mend.14.11.0551)
137. Welboren WJ, Sweep FC, Span PN & Stunnenberg HG 2009 Genomic actions of oestrogen receptor a: what are the targets and how are they regulated? Endocrine-Related Cancer 16 1073-1089. (doi:10.1677/ERC-09-0086)
138. Williams PA, Cosme J, Sridhar V, Johnson EF & McRee DE 2000 Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Molecular Cell 5 121-131. (doi:10.1016/S1097-2765(00)80408-6)
139. Wilson RA. 1968 Feminine forever. New York, NY, USA: M Evans and Company.
140. Wu Q, Chambliss K, Umetani M, Mineo C & Shaul PW 2011 Non-nuclear oestrogen receptor signaling in the endothelium. Journal ofBiological Chemistry 286 14737-14743. (doi:10.1074/jbc.R110.191791)
141. Yager JD. 2012 Mechanisms relating oestrogen to breast cancer. Translational Endocrinology & Metabolism 3 75-93.
142. Yager JD & Chen JQ. 2007 Mitochondrial oestrogen receptors – new insights into specific functions. Trends in Endocrinology and Metabolism 18 89-91. (doi:10.1016/j.tem.2007.02.006)
143. Yager JD & Davidson NE 2006 Estrogen carcinogenesis in breast cancer. New England Journal ofMedicine 354 270-282. (doi:10.1056/NEJMra050776)
144. Yang SH, Liu R, Perez EJ, Wen Y, Stevens SM Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, Will Y, Dykens J et al. 2004 Mitochondrial localization of oestrogen receptor b. PNAS 101 4130-4135. (doi:10.1073/pnas.0306948101)
145. Yoshimoto FK & Guengerich FP 2014 Mechanism of the third oxidative step in the conversion of androgens to oestrogen by cytochrome P450 19A1 steroid aromatase. Journal ofthe American Chemical Society 136 15016-15025. (doi:10.1021/ja508185d)
146. Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, Conaway M, Wang H, Korach KS, Bocchinfuso W et al. 2010 Effects of oestrogen on breast cancer development: role ofoestrogen receptor independent mechanisms. International Journal of Cancer 127 1748-1757. (doi: 10.1002/ijc.25207)
147. Zondek B 1934 Oetrogenic hormone in the urine ofthe stallion. Nature 133 494. (doi:10.1038/133494a0)